ARCHIVES

“What Is Good For NCI Is Good For NIH,” Broder Says In Address

This article is from The Cancer Letter archive.

Vol. 21 No. 02 | January 13, 1995

Download PDF Visit The Full Archive

Related Articles

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

March 2, 2001

NCI Drops Two CCOPS, Cincinnati And West Virginia, For Lack Of Patient Entry; 60 Funded Another Year

August 24, 1984

Novel Four Drug Combination Safe For Lung Cancer Therapy

November 28, 2008

‘Be Careful We’re Not Fighting Old Battles’ On Study Section Issue

September 20, 1991

CALGB Says Results In Adjuvant Setting Too Preliminary; Follow Up Planned In Three Years

April 16, 1999

DCBDC Advisors Table Gl SPORE Over Pancreatic Cancer Research Requirement

March 17, 1995